Improvements in quality of life are maintained in alemtuzumab-treated RRMS patients who develop autoimmune adverse events: CARE-MS 2 - Singer, B; Giovannoni, G; Hatung, H-P; Margolin, D H; Kasten, L; Cohen, J A
Poster presented at: Annual Meeting of the Consortium of Multiple Sclerosis Centers; May 29, 2015; Indianapolis, IN